An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.
We report here a study of peripheral type benzodiazepine receptors (pBZr) in mononuclear cells (MNC) from blood of patients with multiple sclerosis (MS) during periods of stable and active disease and from normal controls. Most active MS patients were retested in a longitudinal study, both during a treatment with high dose steroids and while medication free. Active MS produces a significant decrease of receptor density compared with the controls whereas remission of the disease shows no effect. Four weeks of steroid treatment restore binding density to normal levels, and two weeks of drug withdrawal result in a small, but significant increase in number of the binding sites compared with the control value. We suggest that the number of pBZr in blood MNC might change during the clinical course and steroid therapy of MS.
Ferrero
P
P
Istituto di Clinica delle Malattie del Sistema Nervoso, Università di Torino.
Rocca
P
P
Benna
P
P
De Leo
C
C
Montalenti
E
E
Ravizza
L
L
Bergamasco
B
B
D000328:Adult; D002462:Cell Membrane / Q000378:metabolism; D006801:Humans; D007546:Isoquinolines / Q000378:metabolism; D007700:Kinetics; D009000:Monocytes / Q000378:metabolism*; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism*; D013256:Steroids / Q000009:adverse effects* / Q000627:therapeutic use
D007546:Isoquinolines; D011963:Receptors, GABA-A; D013256:Steroids; C037850:PK 11195